$1.06
0.48% today
Nasdaq, Apr 01, 06:46 pm CET
ISIN
US15117N5032
Symbol
IMNN

Celsion Corporation Stock price

$1.05
+0.16 17.88% 1M
-0.01 0.94% 6M
+0.10 10.53% YTD
-0.88 45.60% 1Y
-4.01 79.25% 3Y
-12.51 92.26% 5Y
-559.65 99.81% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.04 3.67%
ISIN
US15117N5032
Symbol
IMNN
Sector

Key metrics

Market capitalization $15.35m
Enterprise Value $10.62m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.59
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-19.13m
Free Cash Flow (TTM) Free Cash Flow $-18.88m
Cash position $5.87m
EPS (TTM) EPS $-1.65
P/E forward negative
Short interest 6.92%
Show more

Is Celsion Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Celsion Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Celsion Corporation forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Celsion Corporation forecast:

Buy
100%

Financial data from Celsion Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.72 0.72
36% 36%
-
-0.72 -0.72
-
-
- Selling and Administrative Expenses 6.06 6.06
34% 34%
-
- Research and Development Expense 12 12
3% 3%
-
-18 -18
9% 9%
-
- Depreciation and Amortization 0.72 0.72
-
-
EBIT (Operating Income) EBIT -19 -19
9% 9%
-
Net Profit -19 -19
5% 5%
-

In millions USD.

Don't miss a Thing! We will send you all news about Celsion Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Celsion Corporation Stock News

Neutral
GlobeNewsWire
8 days ago
First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer
Neutral
Seeking Alpha
about one month ago
Imunon, Inc. (NASDAQ:IMNN ) Q4 2024 Results Conference Call February 26, 2025 11:00 AM ET Company Participants Peter Vozzo - ICR Healthcare, IR Stacy Lindborg - President & Chief Executive Officer Douglas Faller - Chief Medical Officer David Gaiero - Interim Chief Financial Officer Michael Tardugno - Executive Chairman Khursheed Anwer - Chief Scientific Officer Conference Call Participants Davi...
Neutral
GlobeNewsWire
about one month ago
IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer
More Celsion Corporation News

Company Profile

Celsion Corp . is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Head office United States
CEO Stacy Lindborg
Employees 25
Founded 1982
Website imunon.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today